Pharmaceuticals

Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-402257 for the Treatment of ER+/HER2- Breast Cancer

NEW YORK, Jan. 10, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to CFI-402257, a best in class inhibitor of Threonine Tyrosine Kinase (TTK, also known as Mps...

2023-01-10 21:00 4131

CSafe Bolsters Its Digital Ecosystem Launching TracSafe Data Loggers and CSafe Connect Portal

TracSafe fit-for-purpose data loggers link directly to the comprehensive CSafe Connect customer portal creating the next iteration of a progressive customer-focused digital ecosystem MONROE, Ohio, Jan. 10, 2023 /PRNewswire/ -- CSafe, the largest provider of a complete range of active and passive ...

2023-01-10 20:00 5124

Sarah Otten Joins Medison Pharma as VP, GM Americas Region

Sarah Otten will lead Medison's Americas region covering Canada and Latin America. Sarah brings vast geographical expansion experience in international markets. PETACH TIKVAH, Israel and ZUG, Switzerland, Jan. 9, 2023 /PRNewswire/ -- Medison Pharma ("Medison"), a...

2023-01-10 19:54 2799

Clarivate Identifies Fifteen Potential Blockbuster Drugs in Annual Drugs to Watch Report

Report highlights personalized medicines ensuring greater efficacy for rare diseases and previously untreatable conditions Promising therapeutic developments for HIV, Parkinson's disease, Crohn's disease, alopecia, multiple myeloma and breast cancer on horizon LONDON, Jan. 10, 2023 /PRNewswire/ ...

2023-01-10 16:00 2652

Bangkok Dusit Medical Services extends partnership with CNN to explore global health issues

HONG KONG, Jan. 10, 2023 /PRNewswire/ -- Bangkok Dusit Medical Services Public Company Limited (BDMS), the largest healthcare network inThailand, reinforces its long-standing partnership with CNN International Commercial (CNNIC) with the sponsorship of 'Vital Signs

2023-01-10 11:24 3243

Insilico Medicine Announces Positive Topline Results of the New Zealand Phase I Trial of INS018_055, an AI-Designed Drug for an AI-Discovered Target

NEW YORK and HONG KONG, Jan. 10, 2023 /PRNewswire/ -- Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug R&D company, today announces positive topline results of safety, tolerability, and pharmacokinetics (PK) from thePhase I clinical trial of INS018_055

2023-01-10 05:00 7230

Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes

ROCKVILLE, Md. and SUZHOU, China, Jan. 10, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...

2023-01-10 00:00 4715

Luye Pharma's Innovative Anti-Cancer Therapy Lurbinectedin to Benefit "Named Patients" in Hong Kong

HONG KONG, Jan. 9, 2023 /PRNewswire/ -- Luye Pharma Group today announced the launch of the Named Patient Program (NPP) inHong Kong, China, providing eligible local patients immediate access to the innovative anti-cancer therapy Lurbinectedin. Luye Pharma has signed an agreement with Abacus Medic...

2023-01-09 18:57 5683

Parnell Pharmaceuticals Holdings Ltd Announces Extension of Rights Offering

SYDNEY, Jan. 6, 2023 /PRNewswire/ -- Parnell Pharmaceuticals Holdings Ltd (OTC Pink® Open Market: PARNF) ("Parnell") today announced the extension of the backstopped rights offering to raise gross proceeds of approximatelyUS$4.0 million (the "Rights Offering"). Under the terms of the Rights Offer...

2023-01-06 15:05 5157

Innovent Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib (PI3Kδ inhibitor) for the Treatment of Relapsed or Refractory Follicular Lymphoma

ROCKVILLE, Md. and SUZHOU, China, Jan. 6, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...

2023-01-06 12:22 5136

Kira to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced that Frederick Beddingfield M.D., Ph.D., Chief Executive Officer, will present a...

2023-01-05 23:30 3757

AMR Action Fund Announces Investment in BioVersys AG

Deal marks Fund's first investment in Europe and advances its mission of enabling the launch of two to four antimicrobials by 2030 BOSTON, Jan. 5, 2023 /PRNewswire/ --  The AMR Action Fund, the world's largest public-private partnership investing in biotech companies that are developing antimicr...

2023-01-05 20:00 8772

Dr. Steve Mark Gan and Gan Advanced Osseointegration Center (GAOC) Group of Companies Honored at the Asia Pacific Enterprise Awards 2022 Regional Edition

SINGAPORE, Jan. 5, 2023 /PRNewswire/ -- Enterprise Asia, the organizer of the Asia Pacific Enterprise Awards (APEA) 2022 Regional Edition, is pleased to recognize 25 exemplary business leaders and enterprises acrossAsia which excelled and showcased unparalleled resilience and growth despite the C...

2023-01-05 17:28 3265

Innovent Announces NMPA's Breakthrough Therapy Designation for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Previous Treated Advanced Non-small Cell Lung Cancer

ROCKVILLE, Md. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...

2023-01-05 08:00 5562

DiscGenics to Present at 41st Annual J.P. Morgan Healthcare Conference

SALT LAKE CITY, Jan. 5, 2023 /PRNewswire/ -- DiscGenics, Inc., a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it w...

2023-01-05 08:00 2733

Cognos Therapeutics, Inc. to Become Publicly Listed on Nasdaq via Business Combination with Nocturne Acquisition Corporation

* Cognos Therapeutics is a medical technology company focused on developing unique, radically advanced devices for the treatment of neurological diseases including brain and spinal cancers, and degenerative neurological conditions (such as Alzheimer's and Parkinson's disease), epilepsy, and str...

2023-01-05 07:10 5258

Innovent to Present at 41st Annual J.P. Morgan Healthcare Conference

ROCKVILLE, Md. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, o...

2023-01-05 00:00 3371

Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program

* Synaffix to provide Hummingbird Bioscience access to proprietary ADC technologies * Synaffix to receive up to $150m in upfront and milestone payments plus royalties  SAN FRANCISCO, HOUSTON and SINGAPORE, Jan. 4, 2023 /PRNewswire/ -- Synaffix B.V. (Synaffix), a biotechnology company focused ...

2023-01-04 21:00 3171

China's optimization of control measures lays solid foundation for COVID-19 response

BEIJING, Jan. 4, 2023 /PRNewswire/ -- A report from People's Daily: Local authorities and relevant departments inChina have been making unremitting efforts recently to ensure the supply of medical resources, satisfy the demand for medicines and focus on the prevention and treatment of high-risk g...

2023-01-04 15:39 3093

Pulnovo Medical Announces Dr. Mingdong Zhang, Former FDA Medical Device Officer Joins Scientific Advisory Board

SHANGHAI, Jan. 4, 2023 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM platform, announced the appointment of Dr.Mingdong Zhang to the company's Scientific Advisory Board (SAB). Dr. Zhang will provide guidance on Pulnovo Medical's clinical development and registration strategya...

2023-01-04 10:46 3099
1 ... 124125126127128129130 ... 184